Pure Global AI
NCT05786443Not yet recruiting

Safety and Efficacy of Empagliflozin in Hemodialysis

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Empagliflozin Among Patients Initiating Hemodialysis for the Treatment of End-Stage Kidney Disease
NYU Langone HealthPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
End Stage Renal Disease
Drug/Device/Intervention
Empagliflozin 10 MG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
NYU Langone Health
Location
Boston,New York, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 01, 2023
End date
Dec 30, 2025
Enrollment
60 participants
Primary outcome

Change in Extracellular Volume from Baseline to 12 Weeks,Change in Intracellular Volume from Baseline to 12 Weeks,Change in Total Body Water from Baseline to 12 Weeks,Change in 24-Hour Urine Volume from Baseline to 12 Weeks

Summary

A 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to
 assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo
 among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.

ICD-10 classifications
Chronic kidney disease, stage 1Chronic kidney disease, stage 5Chronic kidney disease, stage 2Chronic kidney disease, stage 3Chronic kidney disease, stage 4
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05786443
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05786443 through Pure Global AI's free database. This Phase 2 trial is sponsored by NYU Langone Health and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.